Introduction
Pre-eclampsia, which is characterised by hypertension and proteinuria, occurs in 3-5% of pregnancies.
1 The condition may be life threatening to the mother and the fetus if it is not properly managed, but it usually ends when the baby and placenta are delivered. 2 The causes of pre-eclampsia are not well understood. A paradoxical preventive effect when the mother smokes has been established, even though the mechanism is unknown. 3 4 Maternal and fetal genes, including paternal genes expressed in the fetus, probably also play a part. 1 5 A high risk of recurrence of pre-eclampsia in subsequent pregnancies supports the role of an inherited susceptibility in the maternal genes. In a previous study in Norwegian women we reported a 12-fold increase in the risk of pre-eclampsia in a second pregnancy when the woman had had preeclampsia in the first pregnancy. 6 A strong association of risks between sisters (odds ratio 2.2) and an increased occurrence of pre-eclampsia in daughters of mothers who had pre-eclampsia are further evidence of maternal genes for susceptibility. 6 7 Paternal genes transmitted to the fetus also seem to be involved in pre-eclampsia. Our earlier study found that the risk of women having pre-eclampsia in their second pregnancy after having had pre-eclampsia in the first pregnancy was 12-fold higher when the fathers were the same in both pregnancies, compared with eightfold higher when the father was different. 6 Furthermore, the risk of pre-eclampsia in any pregnancy was 1.8-fold higher when the father had previously fathered a pre-eclamptic pregnancy in another woman. 6 Similar results have been reported in a study in California. 8 Long term survival of mothers was addressed in 1976 by Chesley et al, who found no increased mortality in white women who had eclampsia in their first pregnancy. 9 In 1981 Fisher et al expressed the view that the long term prognosis of cardiovascular disease in women with pre-eclampsia does not differ from that in the general population. 10 On the other hand, Roberts and Cooper recently proposed common risk factors for pre-eclampsia and atherosclerosis. 1 The set of genes that expresses thrombophilia is a candidate for susceptibility to pre-eclampsia. 11 Women with complications in pregnancy associated with intervillous or spiral artery thrombosis and inadequate placental perfusion and with pre-eclampsia have more mutations of these genes. 12 Genetic thrombophilia may, however, also increase a mother's risk of cardiovascular disease later in life. Specific fetal or paternal candidate genes have so far not been identified.
We followed up mothers and fathers of preeclamptic pregnancies to assess whether their risks of death from specific types of disease were higher than in parents of pregnancies without pre-eclampsia. Any such risk would shed light on factors involved in pre-eclampsia. Increased risk may, however, be associated with the secondary effects of pre-eclampsia. The evidence is increasing that mothers' exposure to hormones during pregnancy, [13] [14] [15] particularly when the women have pre-eclampsia, 16 affects their long term risk of having cancer. In our study we firstly compared the estimated total mortality of mothers and fathers of pre-eclamptic pregnancies with that of mothers and fathers of normal pregnancies. We then separately compared mortality from cardiovascular disease and from cancer in the same groups.
Materials and methods
Data on the cohorts were derived from the medical birth registry of Norway, which comprises all births in Norway since 1967 with more than 16 weeks of gestation (about 60 000 births a year), and from the registry of causes of death. Midwives and doctors must notify the birth registry of a range of personal and medical data.
17 National identification numbers of child and mother are recorded for all births. The father's identification number is usually recorded but was missing in 13.9% of records of first births.
Most diagnoses of pre-eclampsia are notified as such to the medical birth registry. The notification form may also hold information on specific symptoms of pre-eclampsia, such as hypertension induced by pregnancy, proteinuria, and oedema. We defined cases of pre-eclampsia as all pregnancies with a specified diagnosis of pre-eclampsia and all pregnancies in which both hypertension induced by pregnancy and proteinuria were recorded. Birth weight was notified in 99% of birth records. Gestational age, based on the last menstruation, was recorded in more than 90% of births.
Mothers and fathers were divided into two groups according to whether the mother had pre-eclampsia during the pregnancy that resulted in her first delivery. Severe pre-eclampsia is likely to result in a preterm birth (less than 37 weeks' gestation). To identify pregnancies with severe pre-eclampsia we also stratified the cohorts by whether the delivery was term or preterm.
Using national identification numbers we matched records of parents in the medical birth registry with data from the cause of death registry, which is based on death certificates and specifies up to four diagnosed causes of death. We identified a total of 626 272 mothers whose first delivery was registered between 1967 and 1992. Mortality in this cohort of mothers and in the cohort of 539 316 men who were registered as fathers of these births was followed through to 1992. The length of follow up ranged from 0 to 25 years (median 13 years). As well as total mortality, we looked at mortality from cardiovascular causes, cancer, and stroke.
We defined cardiovascular mortality as all deaths in which the cause was registered as being related to the heart. This included codes 410 to 429 of ICD-8 and ICD-9 (international classification of diseases, 8th and 9th revisions). Cancer mortality included all deaths corresponding to codes 140 to 239.
We estimated survival curves representing total mortality, using the actuarial method, with censoring at the end of 1992. We used the log rank test to test for difference in total mortality. We compared mortality in mothers who had pre-eclampsia in their first pregnancy with mortality in other mothers by using the Cox proportional hazards model, adjusting for mother's age at delivery and year of birth of the baby. Mortality in the fathers was analysed similarly. We also used Cox models to compare mortality from specific causes. We used SPSS for Windows 6.0 to analyse data.
Results
Altogether 4350 deaths occurred among the 626 272 mothers whose first delivery was registered between 1967 and 1992 (6.9 deaths per 1000). The proportions among mothers who had term pregnancies with pre-eclampsia and mothers who had preterm pregnancies with pre-eclampsia were 6.6 and 15.5 per 1000, respectively (table 1) . The reduced survival in mothers who had preterm pregnancies with pre-eclampsia was consistent throughout the 25 years of follow up (figure).
Among mothers who had a term delivery, survival was not lower when pre-eclampsia occurred during the pregnancy. Among mothers who did not have pre-eclampsia, survival was moderately reduced after preterm deliveries. After adjustment for maternal age and year of birth of the baby, Cox model analysis (with mothers who did not have pre-eclampsia and who had a term delivery as the reference group) showed a 1.56-fold higher risk of death (95% confidence interval 1.38 to 1.76) in women who had a preterm delivery but no preeclampsia and a 2.71-fold higher mortality in women who had a preterm delivery and pre-eclampsia (table 2) . No increase in mortality was seen in women who had pre-eclampsia but whose pregnancy went to term. The increased risk of death among women who had pre-eclampsia and a preterm delivery was more marked among women who died from cardiovascular causes: the risk in this group was 8.12-fold higher (4.31 to 15.33) than that in the reference group (women who died from cardiovascular causes and who had term pregnancies without pre-eclampsia). For cardiovascular causes, an increased risk was also shown in mothers who had preeclampsia and a term delivery (1.65-fold; 1.01 to 2.70). The increase was 2.95-fold (2.12 to 4.11) after a pregnancy without pre-eclampsia but that ended in a preterm delivery. Similar but weaker results were seen in mothers who died from stroke (table 2) .
For cancer mortality, the risk was decreased (0.36-fold) in women who had pre-eclampsia and a preterm delivery. Although this reduction was not significant, it contrasted with a significant increase in risk (1.32-fold; 1.10 to 1.58) in women who did not have pre-eclampsia but did have a preterm delivery.
Altogether 9284 deaths occurred among the fathers (17.1 per 1000) (table 1). Whether the mother had pre-eclampsia had no significant effect on the long term survival of the fathers (P for difference = 0.42). Overall mortality among the fathers was higher than that in the mothers partly because the mean age of the fathers was higher. No significantly increased risk of death from cardiovascular causes was seen among men who had fathered a pregnancy in which pre-eclampsia occurred. The reduction in cancer mortality (0.66-fold) among fathers of pregnancies in which pre-eclampsia occurred and that were preterm was less than that in mothers and was not significant.
Discussion
Our findings are consistent with but do not prove the hypothesis that the long term risk of death from cardiovascular causes is associated with a maternal genetic predisposition to pre-eclampsia. The association between mortality and pre-eclampsia may also reflect long term complications of the disease or a common effect of social or environmental conditions.
We found no evidence that a father's risk of death from cardiovascular causes was related to preeclampsia in the mother. Paternal genes in the fetus may increase the risk of pre-eclampsia in a particular pregnancy. 6 Such genes are, however, probably not related to risk of cardiovascular disease.
A tendency of a reduced risk of death from cancer was seen in mothers who had pre-eclampsia. This is consistent with a lower prevalence of smoking among mothers who had pre-eclampsia. 3 4 A reduced risk of death from cancer among fathers of pregnancies in which pre-eclampsia occurred might be related to the mother and father having similar smoking patterns. A protective mechanism related to reduced levels of oestrogen in cases of pre-eclampsia is also consistent with a reduced risk of death from cancer among mothers. 16 Interestingly, this contrasted with an increased risk of death from cancer in mothers whose first pregnancy was preterm but who did not have pre-eclampsia.
Misclassification of outcome might have occurred, in that cardiovascular and cancer causes of death could have been overlooked in the death certificate. However, such misclassification would not be differential and would not bias the relative risk.
The prevalence of pre-eclampsia in first pregnancies, as measured by our methods, concurs with the prevalence found in most other studies and indicates Long term survival of mothers after their first delivery, according to whether they had pre-eclampsia and gestational age of baby at birth (term=37 weeks or more) that our measure of pre-eclampsia was reliable and accurate.
1 18 19 We defined pre-eclampsia stringently by excluding pregnancies in which only hypertension induced by pregnancy or hypertension combined with oedema occurred and by including only mothers' first births.
Confounding might explain the strong association between pre-eclampsia and increased cardiovascular mortality in mothers. Smith et al found a negative association between weight at birth of babies and long term cardiovascular mortality of their mothers. 20 21 Thus, the association with pre-eclampsia might also be an effect of birth weight, or mechanisms related to birth weight. 19 In our data pre-eclampsia had an independent effect on cardiovascular mortality, even after adjustment for birth weight (a 2.59-fold higher risk in mothers who had preterm births and pre-eclampsia; P = 0.005). Adjustment for birth weight could be overadjustment, because reduced birth weight would be an effect and a marker of more severe pre-eclampsia. In any case, there is no reason to consider birth weight as a confounder. On the other hand, the existence of other factors causing both pre-eclampsia and increased mortality cannot be further elucidated.
That cardiovascular mortality in women who had preterm deliveries but no pre-eclampsia was higher than in women who had a term delivery and pre-eclampsia justifies further speculation. Underreporting of pre-eclampsia in preterm deliveries would bias the effect of preterm deliveries towards higher relative risks. Alternatively, increased cardiovascular mortality could be due to more than one factor: in preeclampsia it may be related to genetic thrombophilia, and in preterm deliveries it may be related to other factors (smoking, for example, even though it is not generally agreed that smoking and preterm deliveries are related 22 ). Increased cancer mortality (as well as increased cardiovascular and stroke mortality) is consistent with such a hypothesis. Furthermore, if smoking masks the symptoms of pre-eclampsia, a special reason for underreporting would exist that would provide further evidence of the role of genetic thrombophilia. 4 One important limitation of this study is the incomplete follow up of the cohort. The maximum follow up was 26 years, and the median was about 13 years. Although our results apply only to relatively young women, the implications for prevention of preeclampsia and determination of its causes may still be important. With longer follow up the pattern of risks may become clearer but may also change. We followed parents from the mother's first delivery, partly for simplicity and partly because pre-eclampsia is more likely to occur in a mother's first pregnancy. 2 It is possible that the risk of death in the long term changes with outcome in subsequent pregnancies.
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Pre-eclampsia and cardiovascular disease later in life: who is at risk?
James M Roberts
Irgens and associates again use data from the Norwegian birth registry to provide fascinating insights into pre-eclampsia. They previously established that maternal and paternal genes are involved in pre-eclampsia, and they now test the relation between pre-eclampsia and later cardiovascular disease. 1 They report that women with pre-eclampsia who have a preterm delivery have an increased risk of cardiovascular disease, whereas women with pre-eclampsia who deliver at term have no increased risk. The paper has important implications, but the generalisability of the findings must be considered carefully.
The authors provide considerable support for the idea that the onset of pre-eclampsia early and late in pregnancy indicates different diseases. Although this idea has long been the suspicion of clinicians caring for women with pre-eclampsia, only recently has it been supported by objective data. In a study of the relation between birth weight and gestational age in infants, Xiong et al concluded that, compared with births in general, infants were more likely to be underweight only in pre-eclamptic pregnancies that delivered preterm-pregnancies in which pre-eclampsia occurred and that were delivered after 37 weeks actually had a higher proportion of large babies. 2 Irgen et al's findings again emphasise a difference according to gestational age, though this time the difference is in the mother's condition. Their findings also support the relation between pre-eclampsia and preterm birth. Women who delivered preterm but who did not have pre-eclampsia had a higher risk of death from cardiovascular causes. It is sometimes not appreciated that about a third of preterm deliveries are associated with an implantation abnormality identical to that present in pre-eclampsia. 3 The main limitation of this study is the generalisability of the data. The authors support the hypothesis of a relation between cardiovascular disease and pre-eclampsia. They report a strong relation: an eightfold higher risk of death from cardiovascular causes in women with early onset pre-eclampsia, compared with women with normal, term pregnancies.
How do we use these data to counsel women? The women in this study were followed for a median of 13 years. Because these were all first pregnancies, we are dealing with very early onset cardiovascular disease, and therefore many cardiovascular events are likely to occur before menopause. How can this finding be generalised to any patient with preeclampsia? Most women with pre-eclampsia deliver after 37 weeks' gestation, so the finding does not apply to them. In this study women who delivered at term were not at increased risk of death from cardiovascular causes.
What about any woman with pre-eclampsia who has a preterm delivery? The young age at which these cardiovascular events occur raises the possibility that even among women delivering preterm there is a small subset with a high risk, and that most women will not be at increased risk. Is there a way to identify this high risk group? Traditionally, recurrent pre-eclampsia has been the identifying factor for a much higher risk of later cardiovascular disease. A much smaller study found that women with recurrent pre-eclampsia had an 18-fold increased risk of hypertension in later life, compared with women with normal pregnancies. 4 It would be interesting for the authors to look at this subset of women. For now we can conclude that there is a relation between pre-eclampsia and cardiovascular disease in later life, and that this is especially relevant to a subset (as yet unidentified) of those women who have a preterm delivery.
